Brolucizumab
- Generic Name
- Brolucizumab
- Brand Names
- Beovu
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1531589-13-5
- Unique Ingredient Identifier
- XSZ53G39H5
- Background
Brolucizumab, also known as RTH258 or ESBA1008, is a monoclonal antibody indicated to treat neovascular age related macular degeneration.
Brolucizumab was granted FDA approval in October 2019.
- Indication
Brolucizumab is a monoclonal antibody indicated to treat neovascular age related macular degeneration.
- Associated Conditions
- Neovascular Age-Related Macular Degeneration (nAMD)
- Associated Therapies
- -
An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-10-22
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 248
- Registration Number
- NCT04597632
- Locations
- 🇨🇳
Novartis Investigative Site, Taoyuan, Taiwan
Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2020-09-10
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 573
- Registration Number
- NCT04543331
- Locations
- 🇩🇪
Novartis Investigative Site, Wuerzburg, Germany
Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
- First Posted Date
- 2019-09-06
- Last Posted Date
- 2021-03-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT04079231
To Compare Brolucizumab to Aflibercept in Chinese Patients With Visual Impairment Due to Diabetic Macular Edema
- First Posted Date
- 2019-08-15
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 263
- Registration Number
- NCT04058067
- Locations
- 🇨🇳
Novartis Investigative Site, Shanghai, China
Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
- First Posted Date
- 2019-04-17
- Last Posted Date
- 2022-08-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 517
- Registration Number
- NCT03917472
- Locations
- 🇸🇰
Novartis Investigative Site, Zvolen, Slovakia
A Study of the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
- First Posted Date
- 2018-03-29
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 360
- Registration Number
- NCT03481660
- Locations
- 🇹🇷
Novartis Investigative Site, Kocaeli, Turkey
Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
- First Posted Date
- 2018-03-29
- Last Posted Date
- 2023-01-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 566
- Registration Number
- NCT03481634
- Locations
- 🇬🇧
Novartis Investigative Site, Nottingham, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath